| Exclusion Criteria: | 1) Patients who have previously received RAD001 or another mTOR inhibitor.
2) Patients whose tumors have serous carcinomas, mixed malignant mullerian tumors (MMMT) components or uterine sarcomas.
3) Patients who have isolated recurrences (vaginal, pelvic, or para-aortic) that are amenable to potentially curative treatment with radiation therapy or surgery.
4) Patients with a history of psychiatric disorders that would interfere with consent or follow-up.
5) Patients with a history of myocardial infarction within the previous six months or congestive heart failure requiring therapy.
6) Patients with a history of prior malignancy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer) or other cancer for which the patient has been disease-free for at least five years.
7) Pregnant or lactating women. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
8) Patients with a history of seizures are ineligible. Patients receiving phenytoin, phenobarbital, or other anti-epileptic prophylaxis are ineligible.
9) Patients with any other severe concurrent disease which would make the patient inappropriate for entry into this study, including significant hepatic, renal, or gastrointestinal diseases.
10) Patients with deep venous or arterial thrombosis (including pulmonary embolism) within 6 weeks of study entry.
11) Patients with >/= grade 2 hypercholesterolemia or hypertryglyceridemia (fasting state), despite lipid lowering therapy should be excluded from entering the study.
12) Patients currently taking any of the medications listed in Appendix A (Patients will be given a listing of these medicaitons at the time of the informed consent).
13) Known hypersensitivity to everolimus, sirolimus or excipients including hydroxytoluene, magnesium stearate, hydroypropylmethyl-cellulose, crospovidone and lactulose. |